Predictors of heartburn resolution and erosive esophagitis in patients with GERD

Current Medical Research and Opinion

Volumn 25, Issue 9, 2009, Pages 2091-2102

  Orlando, Roy C ^a   Monyak, John T ^b   Silberg, Debra G ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Erosive esophagitis; Esomeprazole; GERD; Heartburn; PPI; Predictive modeling

Indexed keywords

ANTACID AGENT; ESOMEPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ANAMNESIS; ARTICLE; BRONCHITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG FATALITY; DYSPHAGIA; EPIGASTRIC PAIN; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEADACHE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PREDICTION; QUESTIONNAIRE; REFLUX ESOPHAGITIS; SINUSITIS; STOMACH ACID; TREATMENT DURATION; URINARY TRACT INFECTION;

ADULT; AGED; ANTACIDS; ANTI-ULCER AGENTS; ESOPHAGITIS, PEPTIC; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OMEPRAZOLE; PROGNOSIS; RISK FACTORS; YOUNG ADULT;

EID: 69849087903     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903080931     Document Type: Article

References (30)

1. Dean BB, Gano Jr AD, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656-664 (Pubitemid 39013424)
2. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-973
3. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119-224 (Pubitemid 28101879)
4. Armstrong D, Pare P, Pericak D, et al. Symptom relief in gastro-esophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001;96:2849-2857 (Pubitemid 32959523)
5. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - The Genval Workshop Report. Gut 1999;44(Suppl 2):S1-16 (Pubitemid 29151973)
6. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990;335:205-208
7. Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003;17:537-545
8. Barlow WJ, Orlando RC. The pathogenesis of heartburn in non-erosive reflux disease: a unifying hypothesis. Gastroenterology 2005;128:771-778 (Pubitemid 40585379)
9. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002;51:885-892 (Pubitemid 35408615)
10. Malfertheiner P, Lind T, Willich S, et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005;54:746-751 (Pubitemid 40732085)
11. Talley NJ, Armstrong D, Junghard O, et al. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2006;24:371-376 (Pubitemid 43972905)
12. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32:974-979 (Pubitemid 27433659)
13. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33:1023-1029 (Pubitemid 28505643)
14. Labenz J, Jaspersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004;99:1652-1656 (Pubitemid 39237487)
15. World Medical Association. Declaration of Helsinki V: ethical principles for medical research involving human subjects. In: 52nd World Medical Assembly, October 2000; Edinburgh, Scotland, 2000
16. European Agency for the Evaluation of Medicinal Products. International Conference on Harmonisation - World Health Organization, Guideline for Good Practice. ICH Topic E6: Geneva: WHO 2002. Available at: http://www.emea. europa.eu/pdfs/human/ich/013595en.pdf [Last accessed 2 December 2008]
17. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45:172-180 (Pubitemid 29333764)
18. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-665 (Pubitemid 32240711)
19. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-583 (Pubitemid 34245883)
20. Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 2003;18:875-882 (Pubitemid 37346672)
21. Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2004; 2:665-668 (Pubitemid 39013425)
22. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996;111:1192-1199 (Pubitemid 26362243)
23. Cicala M, Emerenziani S, Caviglia R, et al. Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;18:605-613 (Pubitemid 37186610)
24. Gardner JD, Gallo-Torres H, Sloan S, et al. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther 2003;18:891-905 (Pubitemid 37346674)
25. El-Serag HB, Sonnenberg A. Associations between different forms of gastro-oesophageal reflux disease. Gut 1997;41:594-599 (Pubitemid 27496135)
26. Aro P, Ronkainen J, Talley NJ, et al. Body mass index and chronic unexplained gastrointestinal symptoms: an adult endoscopic population based study. Gut 2005;54:1377-1383 (Pubitemid 41375191)
27. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143:199-211 (Pubitemid 41076753)
28. El-Serag HB, Johanson JF. Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative patients with gastroesophageal reflux disease. Scand J Gastroenterol 2002; 37:899-904
29. Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001;96:52-57 (Pubitemid 32104807)
30. Eisen G. The epidemiology of gastroesophageal reflux disease: what we know and what we need to know. Am J Gastroenterol 2001;96(Suppl):S16-8 (Pubitemid 32758202)